Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin plus pioglitazone versus either monotherapy in drug-naive type 2 diabetes
2004-002940-82Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Vildagliptin + pioglitazone, Vildagliptin monotherapy and Pioglitazone monotherapy (3 arms). Primary endpoint: Change in HbA1c from baseline to 24 weeks. Started Nov 2004; status: completed.
02
Drugs
vildagliptinpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2004-002940-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002940-82.